<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phenazopyridine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phenazopyridine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phenazopyridine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10969" href="/d/html/10969.html" rel="external">see "Phenazopyridine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12697" href="/d/html/12697.html" rel="external">see "Phenazopyridine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F208696"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AZO Urinary Pain Relief [OTC] [DSC];</li>
<li>Pyridium;</li>
<li>Urinary Pain Relief [OTC] [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867911"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Phenazo [DSC];</li>
<li>Pyridium</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F208720"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Urinary</li></ul></div>
<div class="block doa drugH1Div" id="F208698"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce2968e8-001c-47bb-8395-538fa72372f2">Diagnostic aid, dye test for identification of urogenital tract injury or fistula</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid, dye test for identification of urogenital tract injury or fistula (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 100 to 200 mg as a single dose for urine staining administered approximately 1 to 2 hours before examination (Abrams 2021; Garely 2022; Ghoniem 2014; Patel 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e18568d-2c88-4edd-a09a-15f8b926cab2">Diagnostic aid, enhanced ureteral and bladder visualization during cystoscopic evaluation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic aid, enhanced ureteral and bladder visualization during cystoscopic evaluation (off-label use):</b></p>
<p style="text-indent:-4em;margin-left:6em;">
<b>Oral:</b> 100 to 200 mg as a single dose administered approximately 1 hour prior to cystoscopy (Espaillat-Rijo 2016; Hui 2009; Propst 2016; Strom 2019). <b>Note:</b> Successful urine staining with phenazopyridine 200 mg (single dose) has been described up to 18 hours prior to cystoscopy (Rehfuss 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="151c92e4-87fb-4604-ab52-9851c2c98ad5">Dysuria, symptomatic relief</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysuria, symptomatic relief: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For brief analgesic use, while addressing the underlying cause of dysuria (eg, treatment of a urinary tract infection) <b>or</b> self-limiting causes of dysuria <b>without</b> a urinary tract infection (eg, postcystoscopy discomfort, acute radiation therapy–induced cystitis).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>200 mg 3 times daily for up to 2 days. <b>Note:</b> For postcystoscopy dysuria <b>without</b> urinary tract infection, some experts use for up to 3 days if needed (Fok 2022). In patients with acute radiation therapy–induced cystitis <b>without</b> infection, may consider use in select patients for up to 2 to 3 weeks (Bradley 2022; Shore 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>OTC product labeling:</i> 2 tablets (190 to 199 mg [amount varies based on product]) 3 times daily as needed for up to 2 days.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990828"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary (Golightly 2013; expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;50 mL/minute: Avoid use. Cases of acute kidney injury, hemolytic anemia, and methemoglobinemia have been reported in patients with reduced kidney function (Alano 1970; Chang 2014; Eisinger 1969; Fincher 1989; Gabor 1965; Golightly 2013; Greenberg 1964; Singh 2014; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzability unknown. Avoid use (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzability unknown. Avoid use (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Avoid use (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988041"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F208699"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F208710"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12697" href="/d/html/12697.html" rel="external">see "Phenazopyridine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="151c92e4-87fb-4604-ab52-9851c2c98ad5">Dysuria, symptomatic relief</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dysuria, symptomatic relief: Note:</b> Generally, the use of phenazopyridine is not included by experts as a therapeutic consideration for management of urinary tract infection (UTI) in pediatric patients (AAP 2011; EAU/ESPU [Stein 2015]; Jerardi 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Limited data available in ages &lt;12 years: Oral: 4 mg/kg/dose 3 times daily; maximum dose: 200 mg/dose (Finkelstein 2016; Gal 2007; Gearhart 2010; Leung 2019; Rudolph 1996); some experts suggest a minimum age of 6 years (Gearhart 2010). Limit therapy to 2 days if being used for UTI.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OTC Labeling: </i>Children ≥12 years and Adolescents: Oral: 2 tablets (190 to 199 mg [dose varies by product]) 3 times daily as needed. Limit therapy to 2 days if being used for UTI.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51204738"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: There are no pediatric-specific recommendations; in adults, use is contraindicated in any degree of renal insufficiency. In adults, cases of acute kidney injury, hemolytic anemia, and methemoglobinemia have been reported in patients with reduced kidney function (Alano 1970; Chang 2014; Eisinger 1969; Fincher 1989; Gabor 1964; Golightly 2013; Greenberg 1964; Singh 2014; manufacturer's labeling).</p></div>
<div class="block dohp drugH1Div" id="F51153445"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F208675"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Xanthoderma (Atreya 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal distress (including nausea and vomiting) (Atreya 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration (Atreya 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (Chang 2014), methemoglobinemia (Shahani 2012), pancytopenia (Haigh 2006), sulfhemoglobinemia (Gopalachar 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (hypersensitivity-induced) (Badley 1976), hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Type IV hypersensitivity reaction (Yeung 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotoxicity (including acute interstitial nephritis, acute kidney injury, and renal tubular necrosis) (Atreya 2017, Singh 2014)</p></div>
<div class="block coi drugH1Div" id="F208687"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to phenazopyridine or any component of the formulation; renal insufficiency.</p></div>
<div class="block war drugH1Div" id="F208672"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute renal failure: Acute renal failure has been reported with larger than recommended doses, primarily in patients with preexisting kidney disease, although some reports have occurred in patients without preexisting kidney disease (Alano 1970; Holmes 2014; Onder 2006). Acute renal failure secondary to phenazopyridine toxicity is usually accompanied by hemolytic anemia, yellow discoloration of the skin, and methemoglobinemia, although acute renal failure can occur in isolation (Holmes 2014). Acute renal failure has also been reported following use of usual recommended doses in patients without preexisting kidney impairment (Shahani 2012; Singh 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Urine discoloration: A reddish-orange discoloration of the urine occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Yellow discoloration: Drug should be discontinued if skin or sclera develop a yellow color (may indicate drug accumulation due to impaired renal excretion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use is contraindicated in patients with kidney impairment (although a specific degree of impairment is not defined in the manufacturer's labeling). Use in patients with preexisting chronic kidney disease has been associated with acute kidney injury, hemolytic anemia, and methemoglobinemia (Chang 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults due to potential for accumulation in patients with renal insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Use caution in patients with G6PD deficiency; hemolytic anemia may occur in the setting of chronic overdose. OTC labeling recommends use only when directed by physician.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lenses: Staining of contact lenses may occur if handled after touching tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">• Limitations of use: Does not treat urinary infection, acts only as an analgesic.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication, patients should be instructed to discontinue use if symptoms last for more than 2 days or if an adverse reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Staining: May stain fabric or clothing.</p></div>
<div class="block foc drugH1Div" id="F208682"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">AZO Urinary Pain Relief: 99.5 mg [DSC] [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pyridium: 100 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Urinary Pain Relief: 95 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F208668"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F208688"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Phenazopyridine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.32 - $2.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $0.44 - $4.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pyridium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $5.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $6.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867912"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phenazo: 100 mg [DSC], 200 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pyridium: 100 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pyridium: 200 mg</p></div>
<div class="block adm drugH1Div" id="F9603405"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or after meals.</p></div>
<div class="block admp drugH1Div" id="F52613571"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with a full glass of water; take with or after meals to reduce stomach upset.</p></div>
<div class="block use drugH1Div" id="F208684"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Dysuria, symptomatic relief:</b>  Symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.</p></div>
<div class="block off-label drugH1Div" id="F57121897"><span class="drugH1">Use: Off-Label: Adult</span><p>Diagnostic aid, dye test for identification of urogenital tract injury or fistula; Diagnostic aid, enhanced ureteral and bladder visualization during cystoscopic evaluation</p></div>
<div class="block mst drugH1Div" id="F208727"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phenazopyridine may be confused with phenoxybenzamine </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pyridium may be confused with Dyrenium, Perdiem, pyridoxine, pyrithione</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299859"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F208677"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13801080"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. Phenazopyridine crosses the placenta and can be detected in amniotic fluid (Meyer 1991).</p></div>
<div class="block brc drugH1Div" id="F20617728"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if phenazopyridine is present in breast milk.</p></div>
<div class="block dic drugH1Div" id="F208689"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with or after meals.</p></div>
<div class="block pha drugH1Div" id="F208671"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">An azo dye which exerts local anesthetic or analgesic action on urinary tract mucosa through an unknown mechanism</p></div>
<div class="block phk drugH1Div" id="F208686"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: In the liver and other tissues</p>
<p style="text-indent:0em;text-align:justify;">Excretion: Urine (66% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F208690"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Urologin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Karidine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Uroxacin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Azochem | Fenazopiridina</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Urisept</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Phenazopyridine | Phenazopyridine HCL | Pyridium | Sronin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Nexurin | Pyridium | Urogetix</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Sedural</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Phenodyne | Pyridium</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pazodin | Pherdin | Uroclean</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Urisept</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alvena | Azofur | Bioferina | Deslotrim | Fenazopiridin | Fenazopiridina | Fenazopiridina bioresearch | Fenazopiridina bruluart | Lazodina | Pirimir | Urezol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Azo cefasabal | Azopiridin | Fenazopiridina | Pyridium | Urofilm | Uropirid | Uroselect | Urotan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Azomir</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Urilef | Uropin | Uropyrine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nefrecil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Azo standard | Azo urinary pain relief | Phenazopyridin hcl | Phenazopyridin hydrochloride | Phenazopyridine | Phenazopyridine HCL | Prodium | Pyridium | Uricalm | Uristat | Urodol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Urisept</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Phenazalgin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Urisept</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fendiridine | Phenazopyridine | Pyridium | Saldicin | Shoridium</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Iropyzin | Kug | Phenazopyridine | Pyridium | Urodine | Urogen | Uropyridin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33904839">
<a name="33904839"></a>Abrams M, Pope R. Obstetric and gynecologic genitourinary fistulas. <i>Clin Obstet Gynecol</i>. 2021;64(2):321-330. doi:10.1097/GRF.0000000000000623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/33904839/pubmed" id="33904839" target="_blank">33904839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5410400">
<a name="5410400"></a>Alano FA Jr, Webster GD Jr. Acute renal failure and pigmentation due to phenazopyridine (Pyridium). <i>Ann Intern Med</i>. 1970;72(1):89-91. doi:10.7326/0003-4819-72-1-89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/5410400/pubmed" id="5410400" target="_blank">5410400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2015">
<a name="AAP.2015"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21873693">
<a name="21873693"></a>American Academy of Pediatrics Subcommittee on Urinary Tract Infection. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i>Pediatrics. </i>2011;128(3):595-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/21873693/pubmed" id="21873693" target="_blank">21873693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Antonetti.1">
<a name="Antonetti.1"></a>Antonetti AM, Williams BA, Ziebarth AJ, DeCesare SL. Use of phenazopyridine in visualizing ureteral jet stream during cystoscopy [abstract]. <i>Obstet Gynecol</i>. 2016;127(suppl 1):18S. doi:10.1097/01.AOG.0000483320.51918.1c</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28765205">
<a name="28765205"></a>Atreya MR, Al Jaberi N, Claes DJ, Volovelsky O. Case 6: Skin discoloration, methemoglobinemia, and acute interstitial nephritis in a 15-year-old girl. <i>Pediatr Rev</i>. 2017;38(8):389. doi:10.1542/pir.2016-0238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/28765205/pubmed" id="28765205" target="_blank">28765205</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  AZO Urinary Pain Relief (phenazopyridine) [prescribing information]. Cromwell, CT: i-Health Inc; December 2020.</div>
</li>
<li>
<div class="reference">
                  AZO Urinary Pain Relief (phenazopyridine) [prescribing information]. Cromwell, CT: i-Health Inc; received February 2020.</div>
</li>
<li>
<div class="reference">
                  AZO Urinary Pain Relief Maximum Strength (phenazopyridine) [prescribing information]. Cromwell, CT: i-Health Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-990717">
<a name="990717"></a>Badley BW. Phenazopyridine-induced hepatitis. <i>Br Med J</i>. 1976;2(6040):850. doi:10.1136/bmj.2.6040.850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/990717/pubmed" id="990717" target="_blank">990717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley KA, McHaffie DR. Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25516057">
<a name="25516057"></a>Chang LC, Kuo CW, Chau T, Lin SH. Phenazopyridine-induced hemolytic anemia in advanced kidney disease. <i>J Am Geriatr Soc</i>. 2014;62(12):2464-1466. doi:10.1111/jgs.13161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/25516057/pubmed" id="25516057" target="_blank">25516057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29369837">
<a name="29369837"></a>Cohen SA, Carberry CL, Smilen SW. American Urogynecologic Society consensus statement: cystoscopy at the time of prolapse repair. <i>Female Pelvic Med Reconstr Surg</i>. 2018;24(4):258-259. doi:10.1097/SPV.0000000000000529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/29369837/pubmed" id="29369837" target="_blank">29369837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4178260">
<a name="4178260"></a>Eisinger AJ, Jones R. Phenazopyridine-hydrochloride haemolysis. <i>Lancet</i>. 1969;1(7586):151. doi:10.1016/s0140-6736(69)91157-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/4178260/pubmed" id="4178260" target="_blank">4178260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31258945">
<a name="31258945"></a>El-Azab AS, Abolella HA, Farouk M. Update on vesicovaginal fistula: a systematic review. <i>Arab J Urol</i>. 2019;17(1):61-68. doi:10.1080/2090598X.2019.1590033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/31258945/pubmed" id="31258945" target="_blank">31258945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27824741">
<a name="27824741"></a>Espaillat-Rijo L, Siff L, Alas AN, et al. Intraoperative cystoscopic evaluation of ureteral patency: a randomized controlled trial. <i>Obstet Gynecol</i>. 2016;128(6):1378-1383. doi:10.1097/AOG.0000000000001750<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/27824741/pubmed" id="27824741" target="_blank">27824741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2922627">
<a name="2922627"></a>Fincher ME, Campbell HT. Methemoglobinemia and hemolytic anemia after phenazopyridine hydrochloride (Pyridium) administration in end-stage renal disease. <i>South Med J.</i> 1989;82(3):372-374. doi:10.1097/00007611-198903000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/2922627/pubmed" id="2922627" target="_blank">2922627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27026272">
<a name="27026272"></a>Finkelstein JB, Van Batavia JP, Casale P. Is outpatient robotic pyeloplasty feasible? <i>J Robot Surg</i>. 2016;10(3):233-237. doi:10.1007/s11701-016-0577-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/27026272/pubmed" id="27026272" target="_blank">27026272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fok.1">
<a name="Fok.1"></a>Fok CS, Kenton K. Diagnostic cystourethroscopy (cystoscopy) for gynecologic conditions. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14215217">
<a name="14215217"></a>Gabor EP, Lowenstein L, DE Leeuw NK. Hemolytic anemia induced by phenylazo-diamino-pyridine (Pyridium). <i>Can Med Assoc J.</i> 1964;91(14):756-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/14215217/pubmed" id="14215217" target="_blank">14215217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Garely.1">
<a name="Garely.1"></a>Garely AD, Mann WJ Jr. Urogenital tract fistulas in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 1, 2022.</div>
</li>
<li>
<div class="reference">
                  Gearhart JP, Rink RC, Mouriquand DPE, eds. <i>Pediatric Urology</i>. 2nd ed. Library of Congress Cataloging-in-Publication Data; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26019933">
<a name="26019933"></a>Ghoniem GM, Warda HA. The management of genitourinary fistula in the third millennium. <i>Arab J Urol</i>. 2014;12(2):97-105. doi:10.1016/j.aju.2013.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/26019933/pubmed" id="26019933" target="_blank">26019933</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy</i>. Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15886294">
<a name="15886294"></a>Gopalachar AS, Bowie VL, Bharadwaj P. Phenazopyridine-induced sulfhemoglobinemia. <i>Ann Pharmacother</i>. 2005;39(6):1128-1130. doi:10.1345/aph.1E557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/15886294/pubmed" id="15886294" target="_blank">15886294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14171812">
<a name="14171812"></a>Greenberg MS, Wong H. Methemoglobinemia and Heinz body hemolytic anemia due to phenazopyridine hydrochloride. <i>N Engl J Med.</i> 1964;271:431-435. doi:10.1056/NEJM196408272710902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/14171812/pubmed" id="14171812" target="_blank">14171812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16466130">
<a name="16466130"></a>Haigh C, Dewar JC. Multiple adverse effects of pyridium: a case report. <i>South Med J</i>. 2006;99(1):90-92. doi:10.1097/01.smj.0000197299.77949.16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/16466130/pubmed" id="16466130" target="_blank">16466130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24711939">
<a name="24711939"></a>Holmes I, Berman N, Domingues V. Acute Renal Failure and Jaundice without Methemoglobinemia in a Patient with Phenazopyridine Overdose: Case Report and Review of the Literature. <i>Case Rep Nephrol</i>. 2014;2014:845372. doi:10.1155/2014/845372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/24711939/pubmed" id="24711939" target="_blank">24711939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19941709">
<a name="19941709"></a>Hui JYC, Harvey MA, Johnston SL. Confirmation of ureteric patency during cystoscopy using phenazopyridine HCl: a low-cost approach. <i>J Obstet Gynaecol Can</i>. 2009;31(9):845-849. doi:10.1016/S1701-2163(16)34303-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/19941709/pubmed" id="19941709" target="_blank">19941709</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jerardi KE, Jackson EC. Urinary tract infections. In: Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap 553.</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30592257">
<a name="30592257"></a>Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary tract infection in children. <i>Recent Pat Inflamm Allergy Drug Discov</i>. 2019;13(1):2-18. doi:10.2174/1872213X13666181228154940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/30592257/pubmed" id="30592257" target="_blank">30592257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16184185">
<a name="16184185"></a>Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. <i>Bone Marrow Transplant</i>. 2005;36(11):929-937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/16184185/pubmed" id="16184185" target="_blank">16184185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28762575">
<a name="28762575"></a>Malik MA, Sohail M, Malik MT, Khalid N, Akram A. Changing trends in the etiology and management of vesicovaginal fistula. <i>Int J Urol</i>. 2018;25(1):25-29. doi:10.1111/iju.13419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/28762575/pubmed" id="28762575" target="_blank">28762575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1760061">
<a name="1760061"></a>Meyer BA, Gonik B, Creasy RK. Evaluation of phenazopyridine hydrochloride as a tool in the diagnosis of premature rupture of the membranes.<i> Am J Perinatol</i>. 1991;8(5):297-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/1760061/pubmed" id="1760061" target="_blank">1760061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34416936">
<a name="34416936"></a>Patel UJ, Heisler CA. Urinary tract injury during gynecologic surgery: prevention, recognition, and management. <i>Obstet Gynecol Clin North Am</i>. 2021;48(3):535-556. doi:10.1016/j.ogc.2021.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/34416936/pubmed" id="34416936" target="_blank">34416936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27399998">
<a name="27399998"></a>Propst K, Tunitsky-Bitton E, O'Sullivan DM, Steinberg AC, LaSala C. Phenazopyridine for evaluation of ureteral patency: a randomized controlled trial. <i>Obstet Gynecol</i>. 2016;128(2):348-355. doi:10.1097/AOG.0000000000001472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/27399998/pubmed" id="27399998" target="_blank">27399998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16897003">
<a name="16897003"></a>Onder AM, Espinoza V, Berho ME, et al. Acute renal failure due to phenazopyridine (Pyridium) overdose: case report and review of the literature. <i>Pediatr Nephrol</i>. 2006;21(11):1760-1764.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/16897003/pubmed" id="16897003" target="_blank">16897003</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Phenazopyridine tablet [prescribing information]. Arlington, TX: Method Pharmaceuticals; December 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27399998">
<a name="27399998"></a>Propst K, Tunitsky-Bitton E, O'Sullivan DM, Steinberg AC, LaSala C. Phenazopyridine for evaluation of ureteral patency: a randomized controlled trial. <i>Obstet Gynecol</i>. 2016;128(2):348-355. doi:10.1097/AOG.0000000000001472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/27399998/pubmed" id="27399998" target="_blank">27399998</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pyridium (phenazopyridine hydrochloride) [prescribing information]. Bridgewater, NJ: Amneal Specialty; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29501712">
<a name="29501712"></a>Rehfuss A, Mahon J, Sorokin I, Smith C, Stein BS. Phenazopyridine: a preoperative way to identify ureteral orifices. <i>Urology</i>. 2018;115:36-38. doi:10.1016/j.urology.2018.02.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/29501712/pubmed" id="29501712" target="_blank">29501712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23954584">
<a name="23954584"></a>Riachy E, Krauel L, Rich BS, et al. Risk factors and predictors of severity score and complications of pediatric hemorrhagic cystitis. <i>J Urol</i>. 2014;191(1):186-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/23954584/pubmed" id="23954584" target="_blank">23954584</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rudolph AM, Hoffman JIE, Rudolph CD. <i>Rudolph's Pediatrics</i>. 20th ed. McGraw-Hill Professional Publishing; 1996.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22987905">
<a name="22987905"></a>Shahani L, Sattovia S. Acquired methaemoglobinaemia related to phenazopyridine ingestion. <i>BMJ Case Rep</i>. 2012:bcr2012006756. doi:10.1136/bcr-2012-006756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/22987905/pubmed" id="22987905" target="_blank">22987905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27159741">
<a name="27159741"></a>Sharp HT, Adelman MR. Prevention, recognition, and management of urologic injuries during gynecologic surgery. <i>Obstet Gynecol</i>. 2016;127(6):1085-1096. doi:10.1097/AOG.0000000000001425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/27159741/pubmed" id="27159741" target="_blank">27159741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31006341">
<a name="31006341"></a>Shore SN, Britnell SR, Brown JN. Safety analysis of long-term phenazopyridine use for radiation cystitis.<i> J Oncol Pharm Pract</i>. 2020;26(2):306-311. doi:10.1177/1078155219842646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/31006341/pubmed" id="31006341" target="_blank">31006341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24575779">
<a name="24575779"></a>Singh M, Shailesh F, Tiwari U, Sharma SG, Malik B. Phenazopyridine associated acute interstitial nephritis and review of literature. <i>Ren Fail</i>. 2014;36(5):804-807. doi:10.3109/0886022X.2014.890054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/24575779/pubmed" id="24575779" target="_blank">24575779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477258">
<a name="25477258"></a>Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. <i>Eur Urol</i>. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/25477258/pubmed" id="25477258" target="_blank">25477258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29300258">
<a name="29300258"></a>Strom EM, Chaudhry ZQ, Guo R, Maisonet AJ, Holschneider CH, Wieslander CK. Effectiveness of assessing ureteral patency using preoperative phenazopyridine. <i>Female Pelvic Med Reconstr Surg</i>. 2019;25(4):289-293. doi:10.1097/SPV.0000000000000540<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/29300258/pubmed" id="29300258" target="_blank">29300258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794360">
<a name="29794360"></a>Tantitamit T, Huang KG. Easy and effective way to evaluate the urological complication during laparoscopic gynaecologic surgery. <i>J Minim Access Surg</i>. 2018;15(2):177-178. doi:10.4103/jmas.JMAS_242_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/29794360/pubmed" id="29794360" target="_blank">29794360</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Uristat Ultra (phenazopyridine hydrochloride) [prescribing information]. Langhorne, PA: Insight Pharmaceuticals; received September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35174061">
<a name="35174061"></a>Yeung WWY, Wong CSM, Leung WY, Li PH. Delayed-type drug eruption to phenazopyridine (pyridium) confirmed with patch testing. <i>Asia Pac Allergy</i>. 2022;12(1):e10 doi:10.5415/apallergy.2022.12.e10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenazopyridine-drug-information/abstract-text/35174061/pubmed" id="35174061" target="_blank">35174061</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9761 Version 443.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
